Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aflibercept.
Ciombor KK, Berlin J, Chan E. Ciombor KK, et al. Clin Cancer Res. 2013 Apr 15;19(8):1920-5. doi: 10.1158/1078-0432.CCR-12-2911. Epub 2013 Feb 26. Clin Cancer Res. 2013. PMID: 23444216 Free PMC article.
Aflibercept--a decoy VEGF receptor.
Ciombor KK, Berlin J. Ciombor KK, et al. Curr Oncol Rep. 2014 Feb;16(2):368. doi: 10.1007/s11912-013-0368-7. Curr Oncol Rep. 2014. PMID: 24445500 Free PMC article. Review.
A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. Goff LW, et al. Among authors: ciombor kk. Invest New Drugs. 2017 Feb;35(1):95-104. doi: 10.1007/s10637-016-0406-z. Epub 2016 Nov 16. Invest New Drugs. 2017. PMID: 27853997 Free PMC article. Clinical Trial.
Promising New Agents for Colorectal Cancer.
Das S, Ciombor KK, Haraldsdottir S, Goldberg RM. Das S, et al. Among authors: ciombor kk. Curr Treat Options Oncol. 2018 May 11;19(6):29. doi: 10.1007/s11864-018-0543-z. Curr Treat Options Oncol. 2018. PMID: 29752549 Free PMC article. Review.
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das S, Ciombor KK, Haraldsdottir S, Pumpalova Y, Sahin IH, Pineda G, Shyr Y, Lin EP, Hsu CY, Chu SK, Goff LW, Cardin DB, Bilen MA, Fisher GA, Wu C, Berlin J. Das S, et al. Among authors: ciombor kk. Oncologist. 2020 Aug;25(8):669-679. doi: 10.1634/theoncologist.2019-0637. Epub 2020 Jan 14. Oncologist. 2020. PMID: 31943525 Free PMC article.
Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.
Wu C, Williams TM, Robb R, Webb A, Wei L, Chen W, Mikhail S, Ciombor KK, Cardin DB, Timmers C, Krishna SG, Arnold M, Harzman A, Abdel-Misih S, Roychowdhury S, Bekaii-Saab T, Wuthrick E. Wu C, et al. Among authors: ciombor kk. Clin Cancer Res. 2020 Jul 1;26(13):3117-3125. doi: 10.1158/1078-0432.CCR-19-4193. Epub 2020 Apr 6. Clin Cancer Res. 2020. PMID: 32253228 Free PMC article. Clinical Trial.
87 results